Related coverage linked through entity extraction aliases.
Feb 18, 2026
Researchers have identified how the MYC protein helps pancreatic cancer evade immune detection, while a separate team discovered methods to permanently switch off cancer genes in leukemia through epigenetic therapy targeting Menin and DOT1L proteins.
Feb 13, 2026
Researchers have developed attenuated Listeria bacteria therapies that boost innate immune cells to fight cancer. Two approaches target colorectal cancer and pediatric leukemia, with FDA clearance expected soon for trials in children.
Feb 20, 2026
The FDA approved AbbVie's combination of Venclexta and acalabrutinib as the first all-oral, fixed-duration treatment for previously untreated chronic lymphocytic leukemia patients, based on Phase 3 trial data showing 35% reduction in disease progression risk.
Feb 20, 2026
A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.
Feb 20, 2026
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Feb 17, 2026
March of Dimes awarded the 2026 Richard B Johnston Jr, MD Prize to hematologist Leonard Zon for pioneering zebrafish research that illuminated blood development in embryos and led to breakthrough treatments for genetic blood disorders in children.
Feb 14, 2026
Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.
Feb 13, 2026
A new report from the American Cancer Society shows 70% of cancer patients now survive five years or more, marking the first time this milestone has been reached. Improvements are attributed to advances in immunotherapy, CAR T-cell therapy, and expanded screening programs.
